|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Jan 11, 2024
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
Q4 FY2021
As of Jun 30, 2021
|
Q3 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Current assets: | |||||||||||||
| Cash | |||||||||||||
| Prepaid expenses | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Accounts receivable, net of allowance for doubtful accounts of $126 and $353 as of September 30, 2022 and June 30, 2022, respectively | |||||||||||||
| Restricted cash | |||||||||||||
| Accounts receivable, net of allowance of $415 and $746, respectively | |||||||||||||
| Inventories | |||||||||||||
| Deferred costs, current | |||||||||||||
| Prepaid expenses and other current assets | |||||||||||||
| Total current assets | |||||||||||||
| Marketable securities held in Trust Account | |||||||||||||
| Deferred costs, net of current portion | |||||||||||||
| Investment in non-affiliate | |||||||||||||
| Deferred transaction costs | |||||||||||||
| Property and equipment, net | |||||||||||||
| Intangible assets, net | |||||||||||||
| Goodwill | |||||||||||||
| Other long-term assets | |||||||||||||
| Total assets | |||||||||||||
| Liabilities and Stockholders' Deficit | |||||||||||||
| Current liabilities: | |||||||||||||
| Due to related party | |||||||||||||
| Accounts payable | |||||||||||||
| Accrued liabilities | |||||||||||||
| Term loans, current | |||||||||||||
| Financing obligations, current | |||||||||||||
| Debt, current | |||||||||||||
| Convertible promissory notes | |||||||||||||
| Deferred revenue, current | |||||||||||||
| Total current liabilities | |||||||||||||
| Promissory note – related party | |||||||||||||
| Related party extension loan | |||||||||||||
| Term loans, noncurrent | |||||||||||||
| Term loans, noncurrent | |||||||||||||
| Financing obligations, net of current | |||||||||||||
| PPP loans | |||||||||||||
| Warrant liabilities | |||||||||||||
| Deferred revenue, net of current portion | |||||||||||||
| Warrant liabilities | |||||||||||||
| Deferred revenue, net of current portion | |||||||||||||
| Other long-term liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Common stock subject to possible redemption 1,255,018 and 17,250,000 shares at approximately $10.21 and $10.10 per share redemption value as of June 30, 2022 and December 31, 2021, respectively | |||||||||||||
| Stockholders' deficit: | |||||||||||||
| Common stock, $0.0001 par value–180,000,000 shares authorized as of September 30, 2022 and June 30, 2022, respectively; 50,639,837 and 27,574,417 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively | |||||||||||||
| Common stock, $0.0001 par value-100,000,000,000 and 180,000,000 shares authorized as of March 31, 2024 and June 30, 2023, respectively, and 107,875,894 shares issued with 104,875,894 shares outstanding as of March 31, 2024 and 57,180,531 shares issued and outstanding as of June 30, 2023 | |||||||||||||
| Treasury stock at cost, 3,000,000 and 0 shares held at March 31, 2024 and June 30, 2023, respectively | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders' deficit | |||||||||||||
| Total liabilities and stockholders' deficit |
Loading...
